Global Pediatric Vaccine Market - 2025 -2033
Pediatric Vaccine Market Size
The global pediatric vaccine market size reached US$ 23.25 Billion in 2024 and is expected to reach US$ 38.53 Billion by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033.
Pediatric Vaccine Market Overview
The global pediatric vaccine market is experiencing robust growth, driven by rising awareness of childhood immunization, increasing government initiatives, and ongoing technological advancements in vaccine development. Key factors fueling demand include the growing prevalence of infectious and chronic diseases among children, the introduction of combination and multivalent vaccines, and enhanced R&D efforts by major pharmaceutical companies.
North America currently leads with the largest market share, while the Asia-Pacific region is expected to see significant expansion due to broader vaccination coverage and higher disposable incomes.
Pediatric Vaccine Market Dynamics: Drivers & Restraints
Rising prevalence of infectious diseases is significantly driving the pediatric vaccine market growth
The increasing prevalence of infectious diseases is a major factor driving growth in the pediatric vaccine market, as outbreaks of measles, mumps, rubella, and pertussis continue to underscore the importance of immunization. For instance, Rubella remains the leading vaccine-preventable cause of birth defects worldwide, with an estimated 100,000 infants born each year with congenital rubella syndrome (CRS). Infection with the rubella virus during pregnancy can lead to miscarriage, fetal death, or CRS, with the most severe outcomes occurring when infection happens in the first trimester.
Despite the availability of a safe and cost-effective vaccine, rubella continues to pose a significant public health challenge; in 2022, there were an estimated 17,865 reported cases across 78 countries. This underscores the urgent need for broader vaccine coverage and the introduction of rubella-containing vaccines in countries where they are not yet part of routine immunization programs.
Governments and healthcare organizations are ramping up vaccination efforts to curb transmission, leading to higher adoption rates. Additionally, rising awareness among parents and caregivers about the critical role of vaccines in disease prevention is further accelerating market expansion.
The high treatment cost is hampering the growth of the pediatric vaccine market
The high cost of vaccine development and distribution poses a significant challenge to the pediatric vaccine market, limiting accessibility and slowing adoption rates. The complex research, clinical trials, and regulatory approvals required for vaccine development demand substantial financial investment, making it difficult for manufacturers to introduce new vaccines at affordable prices.
Pediatric Vaccine Market, Segment Analysis
The global pediatric vaccine market is segmented based on disease type, vaccine type, technology, and region.
The multivalent vaccines from the vaccine type segment is expected to hold 51.5% of the market share in 2024 in the pediatric vaccine market
The multivalent vaccines segment is expected to lead the pediatric vaccine market, primarily because these vaccines offer protection against multiple diseases with a single injection, a feature highly valued by healthcare professionals and parents for its convenience and efficiency. This approach simplifies immunization schedules, increases compliance, and improves vaccine coverage, especially in areas with high disease prevalence or limited healthcare access.
Product innovation is a significant driver in this segment, with ongoing advancements in vaccine formulations, such as the development of safer and more effective conjugate and recombinant vaccines, expanding the reach and effectiveness of multivalent options. Pharmaceutical companies are investing heavily in research and development to create new and improved multivalent vaccines, further accelerating market growth. For instance, in November 2024, Abbott India announced the launch of its new pneumococcal conjugate vaccine, PneumoShield 14, in India. Designed for children as young as 6 weeks old, PneumoShield 14 provides broader protection compared to existing vaccines currently available in the country.
Additionally, strong support from government and international immunization programs is helping to promote the adoption of multivalent vaccines, particularly in regions where comprehensive disease prevention is a public health priority
Pediatric Vaccine Market, Geographical Analysis
North America is expected to dominate the global pediatric vaccine market with a 39.7% share in 2024
North America is projected to maintain its dominance in the pediatric vaccine market, supported by a highly advanced healthcare infrastructure, comprehensive immunization programs, and strong government mandates that ensure widespread vaccine coverage among children. For instance, in May 2025, the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) have announced the development of a next-generation universal vaccine platform called Generation Gold Standard. This innovative platform utilizes a beta-propiolactone (BPL)-inactivated, whole-virus approach to advance vaccine technology.
The region’s economic strength enables significant investments in research and development, fostering continuous innovation and rapid adoption of new vaccine technologies.
Additionally, the presence of leading vaccine manufacturers such as Pfizer, Moderna, and Merck ensures a reliable and timely vaccine supply. Public awareness and acceptance of regular childhood immunizations remain high, further contributing to robust vaccination rates and sustained market leadership for North America in the global pediatric vaccine sector.
Asia-Pacific is growing at the fastest pace in the pediatric vaccine market, holding 20.8% of the market share
The Asia-Pacific region is emerging as the fastest-growing market for pediatric vaccines, driven by several important factors. A large and youthful population creates high demand for immunization, while increasing public awareness and strong government initiatives are broadening vaccination coverage. Countries such as India and China are making notable progress in enhancing healthcare infrastructure and affordability, making vaccines more accessible to families across the region.
Furthermore, continuous investments from both public and private sectors, advancements in vaccine technology, and active participation from leading manufacturers are boosting the region’s capacity to address infectious diseases.
Pediatric Vaccine Market Competitive Landscape
Top companies in the pediatric vaccine market include Pfizer Inc., Sanofi, Merck & Co., Takeda Pharmaceutical Company Limited, Indian Immunological Limited, Bharat Biotech, Panacea Biotec, Sinovac Biotech, AstraZeneca, Novartis AG, among others.
Pediatric Vaccine Market, Key Developments
.
The global pediatric vaccine market size reached US$ 23.25 Billion in 2024 and is expected to reach US$ 38.53 Billion by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033.
Pediatric Vaccine Market Overview
The global pediatric vaccine market is experiencing robust growth, driven by rising awareness of childhood immunization, increasing government initiatives, and ongoing technological advancements in vaccine development. Key factors fueling demand include the growing prevalence of infectious and chronic diseases among children, the introduction of combination and multivalent vaccines, and enhanced R&D efforts by major pharmaceutical companies.
North America currently leads with the largest market share, while the Asia-Pacific region is expected to see significant expansion due to broader vaccination coverage and higher disposable incomes.
Pediatric Vaccine Market Dynamics: Drivers & Restraints
Rising prevalence of infectious diseases is significantly driving the pediatric vaccine market growth
The increasing prevalence of infectious diseases is a major factor driving growth in the pediatric vaccine market, as outbreaks of measles, mumps, rubella, and pertussis continue to underscore the importance of immunization. For instance, Rubella remains the leading vaccine-preventable cause of birth defects worldwide, with an estimated 100,000 infants born each year with congenital rubella syndrome (CRS). Infection with the rubella virus during pregnancy can lead to miscarriage, fetal death, or CRS, with the most severe outcomes occurring when infection happens in the first trimester.
Despite the availability of a safe and cost-effective vaccine, rubella continues to pose a significant public health challenge; in 2022, there were an estimated 17,865 reported cases across 78 countries. This underscores the urgent need for broader vaccine coverage and the introduction of rubella-containing vaccines in countries where they are not yet part of routine immunization programs.
Governments and healthcare organizations are ramping up vaccination efforts to curb transmission, leading to higher adoption rates. Additionally, rising awareness among parents and caregivers about the critical role of vaccines in disease prevention is further accelerating market expansion.
The high treatment cost is hampering the growth of the pediatric vaccine market
The high cost of vaccine development and distribution poses a significant challenge to the pediatric vaccine market, limiting accessibility and slowing adoption rates. The complex research, clinical trials, and regulatory approvals required for vaccine development demand substantial financial investment, making it difficult for manufacturers to introduce new vaccines at affordable prices.
Pediatric Vaccine Market, Segment Analysis
The global pediatric vaccine market is segmented based on disease type, vaccine type, technology, and region.
The multivalent vaccines from the vaccine type segment is expected to hold 51.5% of the market share in 2024 in the pediatric vaccine market
The multivalent vaccines segment is expected to lead the pediatric vaccine market, primarily because these vaccines offer protection against multiple diseases with a single injection, a feature highly valued by healthcare professionals and parents for its convenience and efficiency. This approach simplifies immunization schedules, increases compliance, and improves vaccine coverage, especially in areas with high disease prevalence or limited healthcare access.
Product innovation is a significant driver in this segment, with ongoing advancements in vaccine formulations, such as the development of safer and more effective conjugate and recombinant vaccines, expanding the reach and effectiveness of multivalent options. Pharmaceutical companies are investing heavily in research and development to create new and improved multivalent vaccines, further accelerating market growth. For instance, in November 2024, Abbott India announced the launch of its new pneumococcal conjugate vaccine, PneumoShield 14, in India. Designed for children as young as 6 weeks old, PneumoShield 14 provides broader protection compared to existing vaccines currently available in the country.
Additionally, strong support from government and international immunization programs is helping to promote the adoption of multivalent vaccines, particularly in regions where comprehensive disease prevention is a public health priority
Pediatric Vaccine Market, Geographical Analysis
North America is expected to dominate the global pediatric vaccine market with a 39.7% share in 2024
North America is projected to maintain its dominance in the pediatric vaccine market, supported by a highly advanced healthcare infrastructure, comprehensive immunization programs, and strong government mandates that ensure widespread vaccine coverage among children. For instance, in May 2025, the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) have announced the development of a next-generation universal vaccine platform called Generation Gold Standard. This innovative platform utilizes a beta-propiolactone (BPL)-inactivated, whole-virus approach to advance vaccine technology.
The region’s economic strength enables significant investments in research and development, fostering continuous innovation and rapid adoption of new vaccine technologies.
Additionally, the presence of leading vaccine manufacturers such as Pfizer, Moderna, and Merck ensures a reliable and timely vaccine supply. Public awareness and acceptance of regular childhood immunizations remain high, further contributing to robust vaccination rates and sustained market leadership for North America in the global pediatric vaccine sector.
Asia-Pacific is growing at the fastest pace in the pediatric vaccine market, holding 20.8% of the market share
The Asia-Pacific region is emerging as the fastest-growing market for pediatric vaccines, driven by several important factors. A large and youthful population creates high demand for immunization, while increasing public awareness and strong government initiatives are broadening vaccination coverage. Countries such as India and China are making notable progress in enhancing healthcare infrastructure and affordability, making vaccines more accessible to families across the region.
Furthermore, continuous investments from both public and private sectors, advancements in vaccine technology, and active participation from leading manufacturers are boosting the region’s capacity to address infectious diseases.
Pediatric Vaccine Market Competitive Landscape
Top companies in the pediatric vaccine market include Pfizer Inc., Sanofi, Merck & Co., Takeda Pharmaceutical Company Limited, Indian Immunological Limited, Bharat Biotech, Panacea Biotec, Sinovac Biotech, AstraZeneca, Novartis AG, among others.
Pediatric Vaccine Market, Key Developments
- In July 2024, GSK has unveiled its new multichannel campaign, ‘Ab India Banega 7-Star,’ aimed at encouraging parents to protect their children’s future through seven essential vaccinations that guard against 14 serious diseases. These include chickenpox, hepatitis A, hepatitis B, meningitis, measles, mumps, rubella, pneumonia, influenza, diphtheria, tetanus, pertussis, Hib infection, and polio. The campaign highlights the importance of comprehensive immunization for children’s long-term health and well-being.
.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
3.2. Snippet by Disease Type
3.3. Snippet by Vaccine Type
3.4. Snippet by Technology
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Infectious Disease
4.1.1.2. Increasing Awareness and Immunization Programs
4.1.1.3. Advancements in Vaccine Technology
4.1.2. Restraints
4.1.2.1. High Cost of Vaccine Development and Distribution
4.1.2.2. Regulatory Challenges and Approval Delays
4.1.3. Opportunity
4.1.3.1. Expansion in Emerging Markets
4.1.3.2. Collaborations and Partnerships among Market Players
4.1.4. Impact Analysis
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established Leaders with the Largest Marketing Brand
5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. South America
5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
5.5. Supply Chain Analysis
5.6. Pipeline Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
5.9. Unmet Needs and Gaps
5.10. Recommended Strategies for Market Entry and Expansion
5.11. Pricing Analysis and Price Dynamics
6. PEDIATRIC VACCINE MARKET, BY DISEASE TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Infectious Diseases*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Polio
6.2.4. Influenza
6.2.5. Measles
6.2.6. Mumps
6.2.7. Rubella (MMR)
6.2.8. Pneumococcal disease
6.2.9. Human papillomavirus
6.2.10. Hepatitis
6.2.11. Others
6.3. Allergies
7. PEDIATRIC VACCINE MARKET, BY VACCINE TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
7.1.2. Market Attractiveness Index, By Vaccine Type
7.2. Monovalent Vaccines*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Multivalent Vaccines
8. PEDIATRIC VACCINE MARKET, BY TECHNOLOGY
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Live Attenuated Vaccines*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Inactivated Vaccines
8.4. Sub-unit Vaccines
8.5. Toxoid Vaccines
8.6. Conjugate Vaccines
8.7. Others
9. PEDIATRIC VACCINE MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.1.1. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. China
9.4.6.2. India
9.4.6.3. Japan
9.4.6.4. South Korea
9.4.6.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. Brazil
9.5.6.2. Argentina
9.5.6.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
11.1. Market Share Analysis and Positioning Matrix
11.2. Strategic Partnerships, Mergers & Acquisitions
11.3. Key Developments in Product Portfolios and Innovations
11.4. Company Benchmarking
12. COMPANY PROFILES
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.1.1. Geographical Revenue Shares
12.1.3.1.1.1. Revenue Forecasts
12.1.3.1.2. Key Developments
12.1.3.1.2.1. Mergers & Acquisitions
12.1.3.1.2.2. Key Product Development Activities
12.1.3.1.2.3. Regulatory Approvals, etc.
12.1.3.1.3. SWOT Analysis
12.2. Regeneron Pharmaceuticals, Inc.
12.3. F. Hoffmann-La Roche AG
12.4. Formycon AG
12.5. Bayer AG
12.6. Alimera Sciences
12.7. Knight Therapeutics Inc.
12.8. AbbVie
12.9. Samsung Bioepis( LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
3.2. Snippet by Disease Type
3.3. Snippet by Vaccine Type
3.4. Snippet by Technology
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Infectious Disease
4.1.1.2. Increasing Awareness and Immunization Programs
4.1.1.3. Advancements in Vaccine Technology
4.1.2. Restraints
4.1.2.1. High Cost of Vaccine Development and Distribution
4.1.2.2. Regulatory Challenges and Approval Delays
4.1.3. Opportunity
4.1.3.1. Expansion in Emerging Markets
4.1.3.2. Collaborations and Partnerships among Market Players
4.1.4. Impact Analysis
5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established Leaders with the Largest Marketing Brand
5.1.3. Market Leaders with Established Products
5.2. Latest Developments and Breakthroughs
5.3. Regulatory and Reimbursement Landscape
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. South America
5.3.5. Middle East & Africa
5.4. Porter’s Five Forces Analysis
5.5. Supply Chain Analysis
5.6. Pipeline Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
5.9. Unmet Needs and Gaps
5.10. Recommended Strategies for Market Entry and Expansion
5.11. Pricing Analysis and Price Dynamics
6. PEDIATRIC VACCINE MARKET, BY DISEASE TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Infectious Diseases*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Polio
6.2.4. Influenza
6.2.5. Measles
6.2.6. Mumps
6.2.7. Rubella (MMR)
6.2.8. Pneumococcal disease
6.2.9. Human papillomavirus
6.2.10. Hepatitis
6.2.11. Others
6.3. Allergies
7. PEDIATRIC VACCINE MARKET, BY VACCINE TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
7.1.2. Market Attractiveness Index, By Vaccine Type
7.2. Monovalent Vaccines*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Multivalent Vaccines
8. PEDIATRIC VACCINE MARKET, BY TECHNOLOGY
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Live Attenuated Vaccines*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Inactivated Vaccines
8.4. Sub-unit Vaccines
8.5. Toxoid Vaccines
8.6. Conjugate Vaccines
8.7. Others
9. PEDIATRIC VACCINE MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.1.1. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. China
9.4.6.2. India
9.4.6.3. Japan
9.4.6.4. South Korea
9.4.6.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. Brazil
9.5.6.2. Argentina
9.5.6.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
11.1. Market Share Analysis and Positioning Matrix
11.2. Strategic Partnerships, Mergers & Acquisitions
11.3. Key Developments in Product Portfolios and Innovations
11.4. Company Benchmarking
12. COMPANY PROFILES
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.1.1. Geographical Revenue Shares
12.1.3.1.1.1. Revenue Forecasts
12.1.3.1.2. Key Developments
12.1.3.1.2.1. Mergers & Acquisitions
12.1.3.1.2.2. Key Product Development Activities
12.1.3.1.2.3. Regulatory Approvals, etc.
12.1.3.1.3. SWOT Analysis
12.2. Regeneron Pharmaceuticals, Inc.
12.3. F. Hoffmann-La Roche AG
12.4. Formycon AG
12.5. Bayer AG
12.6. Alimera Sciences
12.7. Knight Therapeutics Inc.
12.8. AbbVie
12.9. Samsung Bioepis( LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Pediatric Vaccines Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)
Table 2 Global Pediatric Vaccines Market Value, By Vaccine Type, 2023, 2027 & 2031 (US$ Million)
Table 3 Global Pediatric Vaccines Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)
Table 4 Global Pediatric Vaccines Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 5 Global Pediatric Vaccines Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)
Table 6 Global Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 7 Global Pediatric Vaccines Market Value, By Vaccine Type, 2023, 2027 & 2031 (US$ Million)
Table 8 Global Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 9 Global Pediatric Vaccines Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)
Table 10 Global Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 11 Global Pediatric Vaccines Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 12 Global Pediatric Vaccines Market Value, By Region, 2022-2031 (US$ Million)
Table 13 North America Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 14 North America Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 15 North America Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 16 North America Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 17 South America Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 18 South America Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 19 South America Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 20 South America Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 21 Europe Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 22 Europe Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 23 Europe Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 24 Europe Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 25 Asia-Pacific Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 26 Asia-Pacific Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 27 Asia-Pacific Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 28 Asia-Pacific Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 29 Middle East & Africa Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 30 Middle East & Africa Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 31 Middle East & Africa Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 32 Pfizer Inc. : Overview
Table 33 Pfizer Inc. : Product Portfolio
Table 34 Pfizer Inc. : Key Developments
Table 35 Sanofi SA: Overview
Table 36 Sanofi SA: Product Portfolio
Table 37 Sanofi SA: Key Developments
Table 38 Merck & Co. : Overview
Table 39 Merck & Co. : Product Portfolio
Table 40 Merck & Co. : Key Developments
Table 41 Takeda Pharmaceuticals: Overview
Table 42 Takeda Pharmaceuticals: Product Portfolio
Table 43 Takeda Pharmaceuticals: Key Developments
Table 44 Indian Immunological limited: Overview
Table 45 Indian Immunological limited: Product Portfolio
Table 46 Indian Immunological limited: Key Developments
Table 47 Bharat Biotech: Overview
Table 48 Bharat Biotech: Product Portfolio
Table 49 Bharat Biotech: Key Developments
Table 50 Panacea Biotec: Overview
Table 51 Panacea Biotec: Product Portfolio
Table 52 Panacea Biotec: Key Developments
Table 53 Sinovac Biotech: Overview
Table 54 Sinovac Biotech: Product Portfolio
Table 55 Sinovac Biotech: Key Developments
Table 56 AstraZeneca: Overview
Table 57 AstraZeneca: Product Portfolio
Table 58 AstraZeneca: Key Developments
Table 59 Novartis AG: Overview
Table 60 Novartis AG: Product Portfolio
Table 61 Novartis AG: Key Developments
Table 1 Global Pediatric Vaccines Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)
Table 2 Global Pediatric Vaccines Market Value, By Vaccine Type, 2023, 2027 & 2031 (US$ Million)
Table 3 Global Pediatric Vaccines Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)
Table 4 Global Pediatric Vaccines Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 5 Global Pediatric Vaccines Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)
Table 6 Global Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 7 Global Pediatric Vaccines Market Value, By Vaccine Type, 2023, 2027 & 2031 (US$ Million)
Table 8 Global Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 9 Global Pediatric Vaccines Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)
Table 10 Global Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 11 Global Pediatric Vaccines Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 12 Global Pediatric Vaccines Market Value, By Region, 2022-2031 (US$ Million)
Table 13 North America Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 14 North America Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 15 North America Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 16 North America Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 17 South America Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 18 South America Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 19 South America Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 20 South America Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 21 Europe Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 22 Europe Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 23 Europe Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 24 Europe Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 25 Asia-Pacific Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 26 Asia-Pacific Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 27 Asia-Pacific Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 28 Asia-Pacific Pediatric Vaccines Market Value, By Country, 2022-2031 (US$ Million)
Table 29 Middle East & Africa Pediatric Vaccines Market Value, By Disease Type, 2022-2031 (US$ Million)
Table 30 Middle East & Africa Pediatric Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)
Table 31 Middle East & Africa Pediatric Vaccines Market Value, By Technology, 2022-2031 (US$ Million)
Table 32 Pfizer Inc. : Overview
Table 33 Pfizer Inc. : Product Portfolio
Table 34 Pfizer Inc. : Key Developments
Table 35 Sanofi SA: Overview
Table 36 Sanofi SA: Product Portfolio
Table 37 Sanofi SA: Key Developments
Table 38 Merck & Co. : Overview
Table 39 Merck & Co. : Product Portfolio
Table 40 Merck & Co. : Key Developments
Table 41 Takeda Pharmaceuticals: Overview
Table 42 Takeda Pharmaceuticals: Product Portfolio
Table 43 Takeda Pharmaceuticals: Key Developments
Table 44 Indian Immunological limited: Overview
Table 45 Indian Immunological limited: Product Portfolio
Table 46 Indian Immunological limited: Key Developments
Table 47 Bharat Biotech: Overview
Table 48 Bharat Biotech: Product Portfolio
Table 49 Bharat Biotech: Key Developments
Table 50 Panacea Biotec: Overview
Table 51 Panacea Biotec: Product Portfolio
Table 52 Panacea Biotec: Key Developments
Table 53 Sinovac Biotech: Overview
Table 54 Sinovac Biotech: Product Portfolio
Table 55 Sinovac Biotech: Key Developments
Table 56 AstraZeneca: Overview
Table 57 AstraZeneca: Product Portfolio
Table 58 AstraZeneca: Key Developments
Table 59 Novartis AG: Overview
Table 60 Novartis AG: Product Portfolio
Table 61 Novartis AG: Key Developments
LIST OF FIGURES
Figure 1 Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 2 Global Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 3 Global Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 4 Global Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 5 Global Pediatric Vaccines Market Share, By Region, 2023 & 2031 (%)
Figure 6 Global Pediatric Vaccines Market Y-o-Y Growth, By Disease Type, 2023-2031 (%)
Figure 7 Infectious Diseases Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 8 Allergies Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 9 Global Pediatric Vaccines Market Y-o-Y Growth, By Vaccine Type, 2023-2031 (%)
Figure 10 Monovalent Vaccines Vaccine Type in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 11 Multivalent Vaccines Vaccine Type in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 12 Global Pediatric Vaccines Market Y-o-Y Growth, By Technology, 2023-2031 (%)
Figure 13 Live attenuated Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 14 Inactivated Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 15 Sub-unit Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 16 Toxoid Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 17 Conjugate Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 18 Others Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 19 Global Pediatric Vaccines Market Y-o-Y Growth, By Region, 2023-2031 (%)
Figure 20 North America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 21 Asia-Pacific Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 22 Europe Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 23 South America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 24 Middle East and Africa Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 25 North America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 26 North America Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 27 North America Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 28 North America Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 29 North America Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 30 South America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 31 South America Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 32 South America Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 33 South America Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 34 South America Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 35 Europe Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 36 Europe Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 37 Europe Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 38 Europe Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 39 Europe Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 40 Asia-Pacific Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 41 Asia-Pacific Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 42 Asia-Pacific Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 43 Asia-Pacific Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 44 Asia-Pacific Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 45 Middle East & Africa Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 46 Middle East & Africa Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 47 Middle East & Africa Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 48 Middle East & Africa Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 49 Pfizer Inc. : Financials
Figure 50 Sanofi SA: Financials
Figure 51 Merck & Co. : Financials
Figure 52 Takeda Pharmaceuticals: Financials
Figure 53 Indian Immunological limited: Financials
Figure 54 Bharat Biotech: Financials
Figure 55 Panacea Biotec: Financials
Figure 56 Sinovac Biotech: Financials
Figure 57 AstraZeneca: Financials
Figure 58 Novartis AG: Financials
Figure 1 Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 2 Global Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 3 Global Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 4 Global Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 5 Global Pediatric Vaccines Market Share, By Region, 2023 & 2031 (%)
Figure 6 Global Pediatric Vaccines Market Y-o-Y Growth, By Disease Type, 2023-2031 (%)
Figure 7 Infectious Diseases Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 8 Allergies Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 9 Global Pediatric Vaccines Market Y-o-Y Growth, By Vaccine Type, 2023-2031 (%)
Figure 10 Monovalent Vaccines Vaccine Type in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 11 Multivalent Vaccines Vaccine Type in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 12 Global Pediatric Vaccines Market Y-o-Y Growth, By Technology, 2023-2031 (%)
Figure 13 Live attenuated Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 14 Inactivated Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 15 Sub-unit Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 16 Toxoid Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 17 Conjugate Vaccines Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 18 Others Technology in Global Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 19 Global Pediatric Vaccines Market Y-o-Y Growth, By Region, 2023-2031 (%)
Figure 20 North America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 21 Asia-Pacific Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 22 Europe Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 23 South America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 24 Middle East and Africa Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 25 North America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 26 North America Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 27 North America Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 28 North America Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 29 North America Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 30 South America Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 31 South America Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 32 South America Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 33 South America Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 34 South America Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 35 Europe Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 36 Europe Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 37 Europe Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 38 Europe Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 39 Europe Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 40 Asia-Pacific Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 41 Asia-Pacific Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 42 Asia-Pacific Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 43 Asia-Pacific Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 44 Asia-Pacific Pediatric Vaccines Market Share, By Country, 2023 & 2031 (%)
Figure 45 Middle East & Africa Pediatric Vaccines Market Value, 2022-2031 (US$ Million)
Figure 46 Middle East & Africa Pediatric Vaccines Market Share, By Disease Type, 2023 & 2031 (%)
Figure 47 Middle East & Africa Pediatric Vaccines Market Share, By Vaccine Type, 2023 & 2031 (%)
Figure 48 Middle East & Africa Pediatric Vaccines Market Share, By Technology, 2023 & 2031 (%)
Figure 49 Pfizer Inc. : Financials
Figure 50 Sanofi SA: Financials
Figure 51 Merck & Co. : Financials
Figure 52 Takeda Pharmaceuticals: Financials
Figure 53 Indian Immunological limited: Financials
Figure 54 Bharat Biotech: Financials
Figure 55 Panacea Biotec: Financials
Figure 56 Sinovac Biotech: Financials
Figure 57 AstraZeneca: Financials
Figure 58 Novartis AG: Financials
